X

Drug Profile

ADS 032

Alternative Names: ADS-032; BT-032

Latest Information Update: 21 Jul 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Bacainn Therapeutics
Developer Adiso Therapeutics
Class Anti-inflammatories; Small molecules
Mechanism of Action Inflammasome inhibitors; NLRP1 protein inhibitors; NLRP3 protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Phase 0 Interstitial lung diseases
Preclinical Dermatitis; Inflammation

Most Recent Events

13 Jul 2023 Preclinical trials in Dermatitis in USA (unspecified route)
06 Jul 2023 Adiso Therapeutics plans an IND-enabling study for Inflammation
06 Jul 2023 Adiso Therapeutics plans clinical trials for Inflammation

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com